finanzen.net
25.06.2019 00:30
Bewerten
(0)

Zika Virus Market Spotlight 2019: 10 Licensing and Asset Acquisition Deals Involving Zika Virus Drugs During 2014-2019

DRUCKEN

DUBLIN, June 24, 2019 /PRNewswire/ -- The "Market Spotlight: Zika Virus" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Zika virus market, comprising key pipeline therapies, clinical trials, and licensing and acquisition deals.

Key Takeaways

  • The Zika virus was first reported in continental South America in Brazil in May 2015. In February 2016, between 440,000 and 1,300,000 people were infected in Brazil. In the US, about 225 Zika virus cases were reported in August 2017. In addition, 554 cases were reported in people infected through local mosquito-borne transmission. Furthermore, autochthonous Zika virus transmission was reported in 25 countries in the Americas, Africa, and Asia.
  • In 2016, it was estimated that there were between 508 and 1,778 imported cases in Europe, particularly in France, Portugal, and Italy.
  • The majority of industry-sponsored drugs in active clinical development for Zika virus are in Phase I, with just a single product in Phase II.
  • Therapies in early-to-mid-stage development for Zika virus focus on the immune system and viral antigens. Candidates comprise DNA vaccines such as the National Institutes of Health's Zika Virus Vaccine, GeneOne's GLS-5700, and Inovio's INO-A002; Moderna's mRNA vaccine; Themis Bioscience's recombinant viral vector vaccine; Imutex's AGS-v vaccine; Johnson & Johnson's Ad26.ZIKV.001 vaccine; Takeda's TAK-426 vaccine; Emergent BioSolutions' ZIKV-IG; and Valneva's ZIKV-VLA1601.
  • The overall likelihood of approval of a Phase I antiviral asset is 16.2%, and the average probability a drug advances from Phase III is 75.9%. Drugs, on average, take 8.6 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.
  • There have been 10 licensing and asset acquisition deals involving Zika virus drugs during 2014-19, all of which occurred in either 2016 or 2017. The exclusive 2017 agreement between Emergent BioSolutions and Valneva worth $58.3m for the global rights to Valneva's Zika vaccine technology and ZIKV-VLA1601 was the largest deal.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for Zika virus have been in Phase I.
  • The US leads the number of Zika virus clinical trials globally. The largest share of industry-sponsored clinical trials are ongoing. Takeda and GeoVax have planned one trial each in the Zika virus space.
  • Sanofi leads industry sponsors with three clinical trials for Zika virus, although all of its trials have been terminated.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
Vaccines
Therapeutics

EPIDEMIOLOGY

PIPELINE DRUGS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
GeoVax Collaborates With Enesi Pharma On Needle-Free Vaccines
Bridging The Gap: Cyclenium Pharma
Brazil's Oneway Diagnostica, iBio Collaborate On Virus Diagnostics

CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
Recent events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

For more information about this report visit https://www.researchandmarkets.com/r/tab13n

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/zika-virus-market-spotlight-2019-10-licensing-and-asset-acquisition-deals-involving-zika-virus-drugs-during-2014-2019-300873372.html

SOURCE Research and Markets

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX beendet Tag im Minus -- Wall Street schließt zurückhaltend -- SAP enttäuscht mit ausbleibender Margensteigerung -- Netflix schockt mit Zahl der Neukunden -- Bitcoin, ASOS, Wirecard im Fokus

Bayer-Chef sieht nach Elliott-Kritik kein Grund zum Umdenken. QUALCOMM-Aktie tiefer: EU-Kommission verhängt dreistellige Millionen-Strafe. Heidelberger Druck meldet Gewinnwarnung. eBay kann Erwartungen schlagen. IBM-Umsatz fällt deutlich. EZB prüft wohl neuen Ansatz für Inflationsziel. Munich Re erzielt Milliarden-Gewinn.

Die 5 beliebtesten Top-Rankings

Die 12 toten Topverdiener 2019
Diese Legenden sind die bestbezahlten Toten der Welt
Das hat sich geändert
Diese Aktien hat George Soros im Depot
Big-Mac-Index
In welchen Ländern kostet der Big Mac wie viel?
Die Länder mit den größten Goldreserven 2019
Wer lagert das meiste Gold?
In diesen Berufen bekommt man das niedrigste Gehalt
Welche Branchen man besser meiden sollte.
mehr Top Rankings

Umfrage

Wo sehen Sie den DAX Ende 2019?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
SAP SE716460
Deutsche Bank AG514000
Daimler AG710000
NEL ASAA0B733
Netflix Inc.552484
Microsoft Corp.870747
Amazon906866
Infineon AG623100
TeslaA1CX3T
Apple Inc.865985
BASFBASF11
BayerBAY001
Airbus SE (ex EADS)938914
Heidelberger Druckmaschinen AG731400